Olr358 inhibitors represent a class of compounds characterized by their interaction with the Olr358 receptor, a member of the olfactory receptor family, which is a subset of the G protein-coupled receptor (GPCR) superfamily. These receptors are predominantly expressed in the olfactory epithelium, where they are responsible for the detection of odorants. The inhibition of Olr358 receptors involves compounds that can bind to these receptors, preventing their activation by natural ligands or odorants. The structural diversity of Olr358 inhibitors is significant, encompassing a wide range of chemical scaffolds, including small organic molecules, peptides, and even larger, more complex entities. These inhibitors can function through competitive inhibition, where they directly compete with the natural ligands for the binding site on the Olr358 receptor, or through allosteric modulation, where they bind to a different site on the receptor, inducing conformational changes that reduce the receptor's affinity for its natural ligands.
The study of Olr358 inhibitors is crucial for understanding the molecular mechanisms underlying olfaction and for exploring the broader roles of olfactory receptors beyond the sense of smell. In particular, Olr358 has been shown to be involved in various non-olfactory physiological processes, which has sparked interest in the design and synthesis of specific inhibitors that can modulate this receptor's activity. Advanced techniques in computational chemistry, such as molecular docking and dynamic simulations, have facilitated the identification and optimization of potent Olr358 inhibitors. These techniques enable researchers to predict the binding affinity and selectivity of potential inhibitors, as well as to explore the conformational changes induced in the Olr358 receptor upon inhibitor binding. Moreover, structure-activity relationship (SAR) studies provide valuable insights into the chemical features that are critical for the inhibitory activity, guiding the rational design of more effective inhibitors. The ongoing research into Olr358 inhibitors continues to expand our understanding of GPCR regulation and the diverse functions of olfactory receptors in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity potentially affecting Olr358. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, could influence Olr358 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, may affect GPCR signaling pathways related to Olr358. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, could indirectly affect GPCR pathways including Olr358. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, may influence GPCR-mediated signaling pathways related to Olr358. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olr358 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, may influence GPCR signaling pathways including Olr358. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr358. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr358. | ||||||